An in vitro study on the mechanisms of coagulation activation in acute myelogenous leukemia (AML): Role of tissue factor regulation by cytotoxic drugs and GM-CSF

Thrombosis and Haemostasis

Volumn 92, Issue 5, 2004, Pages 1136-1146

  Langer, Florian ^a,b   Amirkhosravi, Ali ^a   Loges, Sonja ^b   Meyer, Todd ^a   Eifrig, Barbara ^b   Hossfeld, Dieter K ^b   Fiedler, Walter ^b   Francis, John L ^a  

^a FLORIDA HOSPITAL CANCER INSTITUTE   (United States)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Apoptosis; Cytokines; Disseminated intravascular coagulation (DIC) sepsis; Malignancy; Tissue factor factor VII

Indexed keywords

BLOOD CLOTTING FACTOR 7A; CYTARABINE; CYTOTOXIC AGENT; DAUNORUBICIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; PHOSPHATIDYLSERINE; PROUROKINASE; THROMBOPLASTIN; VASCULOTROPIN A;

ACUTE GRANULOCYTIC LEUKEMIA; APOPTOSIS; ARTICLE; BLOOD CLOTTING; BONE MARROW; CANCER PATIENT; CELL DEATH; CELL SURFACE; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CULTURE MEDIUM; CYTOKINE RELEASE; DRUG MECHANISM; DRUG RESPONSE; GENETIC CODE; HUMAN; HUMAN CELL; IN VITRO STUDY; LEUKEMIA CELL LINE; MICROENVIRONMENT; MYELOBLAST; OUTER MEMBRANE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN SYNTHESIS;

ANTINEOPLASTIC AGENTS; BLOOD CELLS; BLOOD COAGULATION; CELL DEATH; CELLS, CULTURED; CYTARABINE; DAUNORUBICIN; GRANULOCYTE PRECURSOR CELLS; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HL-60 CELLS; HUMANS; LEUKEMIA, MONOCYTIC, ACUTE; LEUKEMIA, MYELOCYTIC, ACUTE; LEUKEMIA, MYELOMONOCYTIC, ACUTE; THROMBOPLASTIN;

EID: 9144266359     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH04-04-0215     Document Type: Article

References (44)

1. Lisiewicz J. Mechanisms of hemorrhage in leukemias. Semin Thromb Haemost 1978; 4: 241-67.
2. Chojnowski K, Wawrzyniak W, Trelinski J, et al. Assessment of coagulation disorders in patients with acute leukemia before and after cytostatic treatment. Leuk Lymphoma 1999; 36: 77-84.
3. Barbui T, Falanga A. Disseminated intravascular coagulation in acute leukemia. Semin Thromb Haemost 2001; 27: 593-604.
4. Lisiewicz J. Disseminated intravascular coagulation in acute leukemia. Semin Thromb Haemost 1988; 14: 339-50.
5. Nur S, Anwar M, Saleem M, et al. Disseminated intravascular coagulation in acute leukaemias at first diagnosis. Eur J Haematol 1995; 55: 78-82.
6. Sletnes KE, Godal HC, Wisloff F. Disseminated intravascular coagulation (DIC) in adult patients with acute leukaemia. Eur J Haematol 1995; 54: 34-8.
7. Tanaka M, Yamanishi H. The expression of tissue factor antigen and activity on the surface of leukemic cells. Leukemia Res 1993; 17: 103-11.
8. Bauer KA, Conway EM, Bach R, et al. Tissue factor gene expression in acute myeloblastic leukemia. Thromb Res 1989; 56: 425-30.
9. Falanga A, Alessio MG, Donati MB, et al. A new procoagulant in acute leukemia. Blood 1988; 71: 870-5.
10. Donati MB, Falanga A, Consonni R, et al. Cancer procoagulant in acute non lymphoid leukemia: relationship of enzyme detection to disease activity. Thromb Haemost 1990; 64: 11-6.
11. Carson SD, Pirruccello SJ, Haire WD. Tissue factor antigen and activity are not expressed on the surface of intact cells isolated from an acute promyelocytic leukemia patient. Thromb Res 1990; 59: 159-70.
12. Bradstock KF, Gottlieb DJ. Interaction of acute leukemia cells with the bone marrow microenvironment: implications for control of minimal residual disease. Leuk Lymphoma 1995; 18: 1-16.
13. Hussong JW, Rodgers GM, Shami PJ. Evidence of increased angiogenesis in patients with acute myleoid leukemia. Blood 2000; 95: 309-13.
14. Dias S, Hattori K, Zhu Z, et al. Autocrine stimulation of VEGFR-2 activates human leukemic cell growth and migration. J Clin Invest 2000; 106: 511-21.
15. Fiedler W, Graeven U, Ergun S, et al. Vascular endothelial growth factor, a possible paracrine growth factor in human acute myleoid leukemia. Blood 1997; 89: 1870-5.
16. Onetto-Pothier N, Aumont N, Haman A, et al. Characterization of granulocyte-macrophage colony-stimulating factor receptor on the blast cells of acute myeloblastic leukemia. Blood 1990; 75: 59-66.
17. Rogers SY, Bradbury D, Kozlowski R, et al. Evidence for internal autocrine regulation of growth in acute myeloblsatic leukemia cells. Exp Hematol 1994; 22: 593-8.
18. Tsuzuki M, Ezaki K, Maruyama F, et al. Proliferative effects of several hematopoietic growth factors on acute myelogenous leukemia cells and correlation with treatment outcome. Leukemia 1997; 11: 2125-30.
19. Schiffer CA. Hematopoietic growth factors as adjuncts to the treatment of actute myeloid leukemia. Blood 1996; 88: 3675-85.
20. Witz F, Sadoun A, Perrin MC, et al. for the Groupe Quest Est Leucemies Aigues Myeloblastiques (GOELAM). A placebo-controlled study of recombinant human granulocyte-macrophage colony-stimulating factor administered during and after induction treatment for de novo acute myelogenous leukemia in elderly patients. Blood 1998; 91: 2722-30.
21. Estey E, Thall PF, Kantarjian H, et al. Treatment of newly diagnosed acute myelogenous leukemia with granulocyte-macrophage colony-stimulating factor (GM-CSF) before and during continuous-infusion high-dose ara-C + daunorubicin: comparison to patients treated without GM-CSF. Blood 1992; 79: 2246-55.
22. Barbui T, Finazzi G, Grassi A, et al. Thrombosis in cancer patients treated with hematopoietic growth factors - a meta-analysis. Thromb Haemost 1996; 75: 368-71.
23. Langer F, Morys-Wortmann C, Kusters B, et al. Endothelial protease-activated receptor-2 induces tissue factor expression and von Willebrand factor release. Br J Haematol 1999; 105: 542-50.
24. Fiedler W, Mesters R, Tinnefeld H, et al. A phase 2 clinical study of SU5416 in patients with refractory acute myeloid leukemia. Blood 2003; 102: 2763-7.
25. Bach RR, Moldow CF. Mechanism of tissue factor activation on HL-60 cells. Blood 1997; 89: 3270-6.
26. Le DT, Rapaport SI, Rao LVM. Relations between factor VIIa binding and expression of factor VIIa/tissue factor catalytic activity on cell surfaces. J Biol Chem 1992; 267: 15447-54.
27. Dartsch DC, Schaefer A, Boldt S, et al. Comparison of anthracycline-induced death of human leukemia cells: programmed cell death versus necrosis. Apoptosis 2002; 7: 537-48.
28. Camera M, Giesen PL, Fallon J, et al. Cooperation between VEGF and TNF-alpha is necessary for exposure of active tissue factor on the surface of human endothelial cells. Arterioscler Thromb Vasc Biol 1999; 19: 531-7.
29. Oster W, Cicco NA, Klein H, et al. Participation of the cytokines interleukin 6, tumor necrosis factor-alpha, and interleukin 1-beta secreted by acute myelogenous leukemia blasts in autocrine and paracrine leukemia growth control. J Clin Invest 1989; 84: 451-7.
30. Duhrsen U, Martinez T, Vohwinkel G, et al. Effects of vascular endothelial and platelet-derived growth factor inhibitors on long-term cultures from normal human bone marrow. Growth Factors 2001; 19: 1-17.
31. Spiekermann K, Dirschinger RJ, Schwab R, et al. The protein tyrosine kinase inhibitor SU5614 inhibits FLT3 and induces growth arrest and apoptosis in AML-derived cell lines expressing a constitutively activated FLT3. Blood 2003; 101: 1494-504.
32. Gallagher R, Collins S, Trujillo J, et al. Characterization of the continuous, differentiating myeloid cell line (HL-60) from a patient with acute promyelocytic leukemia. Blood 1979; 54: 713-33.
33. Drexler HG, Quentmeier H, MacLeod RA, et al. Leukemia cell lines: in vitro models for the study of acute promyelocytic leukemia. Leuk Res 1995; 19: 681-91.
34. Wallington LA, Durham J, Bunce CM, et al. Growth of single HL60 cells in liquid culture: analysis of the influence of differentiative agents. Leuk Res 1996; 20: 821-829.
35. Hair GA, Padula S, Zeff R, et al. Tissue factor expression in human leukemic cells. Leuk Res 1996; 20: 1-11.
36. Drake TA, Ruf W, Morrissey JH, et al. Functional tissue factor is entirely cell surface expressed on lipopolysaccharide-stimulated human blood monocytes and a constitutively tissue factor-producing neoplastic cell line. J Cell Biol 1989; 109: 389-95.
37. Fibach E, Treves A, Korenberg A, et al. In vitro generation of procoagulant activity by leukemic promyelocytes in response to cytotoxic drugs. Am J Hematol 1985; 20: 257-65.
38. Wolberg AS, Monroe DM, Roberts HR, et al. Tissue factor de-encryption: ionophore treatment induces changes in tissue factor activity by phosphatidylserine-dependent and -independent mechanisms. Blood Coagul Fibrinolysis 1999; 10: 201-10.
39. Bartkowiak D, Hogner S, Baust H, et al. Comparative analysis of apoptosis in HL60 detected by annexin-V and fluorescein-diacetate. Cytometry 1999; 37: 191-6.
40. Takemori N, Hirai K, Onodera R, et al. Disseminated intravascular coagulation in a patient with acute myeloid leukemia. Am J Clin Pathol 1993; 99: 695-701.
41. Wang J, Weiss I, Svoboda K, et al. Thrombogenic role of cells undergoing apoptosis. Brit J Haematol 2001; 115: 382-91.
42. Greeno EW, Bach RR, Moldow CF. Apoptosis is associated with increased cell surface tissue factor procoagulant activity. Lab Invest 1996; 75: 281-9.
43. Rickles FR, Hair GA, Zeff RA, et al. Tissue factor expression in human leukocytes and tumor cells. Thromb and Haemost 1995; 74: 391-5.
44. Rowe MJ, Neuberg D, Friedenberg W, et al. A phase 3 study of three induction regimens and of priming with GM-CSF in older adults with acute myeloid leukemia: a trial by the Eastern Cooperative Oncology Group. Blood 2004; 103: 479-85.